In the Spotlight

Molecular characterisation of tumour subtypes and immunotherapy are key areas attracting researchers’ efforts that may shape the future of clinical practice, according to ESMO President Prof. Andrés Cervantes 

Teresa Del Giudice is the 30,000^th ESMO Member. In this interview she explains what motivated her to join the community.

Dr Raffaella Casolino is the third ESMO young medical oncologist serving as a cancer expert on the WHO Cancer Control team

Tools and targeted communication are needed to guide clinical practice and help healthcare professionals make sustainable choices

The 2023 ESMO TAT Honorary Awardee Prof. Susan E. Bates gives an overview of the lasting challenges and unfulfilled potential of these therapies  

According to the 2022 awardee, the future of immuno-oncology lies in the modulation of the tumour microenvironment and cancer vaccines 

Moving back and forth across academic and corporate positions has become increasingly common for oncologists in search of new opportunities

Treating patients at reduced doses could contribute to a more efficient allocation of healthcare resources and improve access to costly treatments around the world, but implementation of de-escalation in routine practice requires reliable and cost-effective tools to safely tailor therapy to patients

ESMO developed a classification to assess the risk-benefit ratio of treatment intensity modulation by a three-tiered approach 

Experience in breast cancer shows that treatment de-intensification must follow robust evidence, but also values and preferences to generate acceptance